- Home
- YRD vs RGNX Comparison
YRD vs RGNX Comparison
Compare YRD & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YRD
- RGNX
- Stock Information
- Founded
- YRD 2012
- RGNX 2008
- Country
- YRD China
- RGNX United States
- Employees
- YRD N/A
- RGNX N/A
- Industry
- YRD Finance: Consumer Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YRD Finance
- RGNX Health Care
- Exchange
- YRD Nasdaq
- RGNX Nasdaq
- Market Cap
- YRD 411.2M
- RGNX 356.7M
- IPO Year
- YRD 2015
- RGNX 2015
- Fundamental
- Price
- YRD $7.59
- RGNX $7.27
- Analyst Decision
- YRD
- RGNX Buy
- Analyst Count
- YRD 0
- RGNX 12
- Target Price
- YRD N/A
- RGNX $33.36
- AVG Volume (30 Days)
- YRD 162.3K
- RGNX 698.7K
- Earning Date
- YRD 03-20-2025
- RGNX 02-28-2025
- Dividend Yield
- YRD 2.25%
- RGNX N/A
- EPS Growth
- YRD N/A
- RGNX N/A
- EPS
- YRD 2.95
- RGNX N/A
- Revenue
- YRD $802,340,579.00
- RGNX $84,327,000.00
- Revenue This Year
- YRD N/A
- RGNX $2.23
- Revenue Next Year
- YRD N/A
- RGNX $250.77
- P/E Ratio
- YRD $2.56
- RGNX N/A
- Revenue Growth
- YRD 19.51
- RGNX N/A
- 52 Week Low
- YRD $4.12
- RGNX $6.56
- 52 Week High
- YRD $9.20
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- YRD 79.38
- RGNX 41.90
- Support Level
- YRD $5.40
- RGNX $6.92
- Resistance Level
- YRD $7.97
- RGNX $7.79
- Average True Range (ATR)
- YRD 0.43
- RGNX 0.44
- MACD
- YRD 0.15
- RGNX -0.04
- Stochastic Oscillator
- YRD 85.09
- RGNX 19.40
About YRD Yiren Digital Ltd.
Yiren Digital Ltd is an advanced, AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.